Gilde Healthcare has held the final close of its Gilde Healthcare Venture&Growth VI fund with €740m in total capital commitments. Fund VI reached its hard cap following a first close at €600m in April this year.
The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.
The fund, which is an Article 9 Fund under the Sustainable Finance Disclosure Regulation (SFDR), is backed by a mix of international investors, including healthcare corporates, (Dutch) pension funds, banks, insurers, fund-of-funds, sovereign wealth funds, endowments, family offices, entrepreneurs and the Gilde team.
The new fund will invest €10-70 million per new portfolio company. Together with the previous Venture&Growth fund (closed in 2020) and Gilde Healthcare Private Equity IV (closed in 2022), Gilde Healthcare has raised €1.7 billion in capital over the last three years.